In order to assess the efficacy and safety of JZP-258, a lower sodium alternative product to sodium oxybate, study authors designed a double-blind, placebo-controlled, randomized withdrawal, multicenter study with an open-label safety extension.
Treatment rates for patients with major depressive disorder with an elevated PHQ-9 score were characterized in this study.
SHP465 mixed amphetamine salts reduced symptoms of attention-deficit/hyperactivity disorder in adults, independent of ADHD treatment history.
Researchers evaluated differences in the burden of health outcomes between those with and without depression.
Researchers used data from the National Health and Nutrition Examination Survey 2009-2018 to assess the impact of drug and alcohol use on cardiometabolic disease risk factors.
A retrospective study was conducted to evaluate the demographic predictors of ADHD in hospitalized children with ASD and the impact of comorbidities on length of stay.
Researchers assessed data from short-term studies with open-label extensions among adults and adolescents with bipolar depression to assess the impact of lurasidone on treatment-emergent mania.
Analysis of the HARMONY trial was conducted to evaluate the prevention of relapse in patients with dementia-related psychosis who have been treated with pimavanserin.
Researchers sought to evaluate the prevalence of pre-existing conditions for adverse events and potential drug-drug interactions related to selected atypical antipsychotics and other non-antidepressant agents among adults with treatment-resistant depression.
Extrapyramidal symptoms that developed in patients with schizophrenia after initiation of treatment with atypical antipsychotic agents were associated with increased healthcare resources and costs.
